Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance
Open accessThe DOI matches its Crossref record; 311 of the 318 references it cites were found in a registry or an index.
Abstract
Resistance to targeted therapies is a complex and multifactorial process that culminates in the selection of a cancer clone with the ability to evade treatment. Chronic myeloid leukemia (CML) was the first malignancy recognized to be associated with a genetic alteration, the t(9;22)(q34;q11). This translocation originates the BCR-ABL1 fusion gene, encoding the cytoplasmic chimeric BCR-ABL1 protein that displays an abnormally high tyrosine kinase activity. Although the vast majority of patients with CML respond to Imatinib, a tyrosine kinase inhibitor (TKI), resistance might occur either de novo or during treatment. In CML, the TKI resistance mechanisms are usually subdivided into BCR-ABL1-dependent and independent mechanisms. Furthermore, patients’ compliance/adherence to therapy is critical to CML management. Techniques with enhanced sensitivity like NGS and dPCR, the use of artificial intelligence (AI) techniques, and the development of mathematical modeling and computational prediction methods could reveal the underlying mechanisms of drug resistance and facilitate the design of more effective treatment strategies for improving drug efficacy in CML patients. Here we review the molecular mechanisms and other factors involved in resistance to TKIs in CML and the new methodologies to access these mechanisms, and the therapeutic approaches to circumvent TKI resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“One cluster summarized the concepts related to the development of resistance to chemotherapy drugs, rendering the treatment ineffective in inhibiting cancer cell proliferation or inducing cell death. This discovery has been repeatedly validated through experimental results from BCR-ABL kinase-independent pathways that promote CML cell survival and proliferation, bypassing TKI inhibition [84, 85].”
From GOLDEN fusion: a graph-oriented learning with domain-embedding network fusion for generating super gene sets in functional genomics (2026) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple factors, not necessarily mutually exclusive, can contribute to TKI resistance [46].”
From 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia (2025) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1797280 · Cited by 2,897
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
The multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Autophagy modulation as a potential therapeutic target for diverse diseases
Rubinsztein, D. C., Codogno, P., & Levine, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3802 · Cited by 1,437
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Src family kinases, key regulators of signal transduction
Parsons, S. J., & Parsons, J. T. (2004) · Oncogene · doi:10.1038/sj.onc.1208160 · Cited by 936
Marin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3087 · Cited by 909
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
Heisterkamp, N., Stephenson, J. R., Groffen, J., Hansen, P. F., de Klein, A., Bartram, C. R., & Grosveld, G. (1983) · Nature · doi:10.1038/306239a0 · Cited by 842
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronnie, G. T., Béné, M.-C., De Vos, J., Hernández, J. M., Hofmann, W.-K., Mills, K. I., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4732 · Cited by 654
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
Noens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Mineur, P., Van Eygen, K., MacDonald, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196543 · Cited by 616
Schepers, K., Pietras, E. M., Reynaud, D., Flach, J., Binnewies, M., Garg, T., Wagers, A. J., Hsiao, E. C., & Passegué, E. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.009 · Cited by 614
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 614
Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Hillmen, P., Hallek, M., & Buske, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv303 · Cited by 612
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Pane, F., Müller, M. C., Ernst, T., Rosti, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326405 · Cited by 589
Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584
TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Naka, K., Hoshii, T., Muraguchi, T., Tadokoro, Y., Ooshio, T., Kondo, Y., Nakao, S., Motoyama, N., & Hirao, A. (2010) · Nature · doi:10.1038/nature08734 · Cited by 583
Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. V., Soliera, A. R., Ronchetti, M., Galavotti, S., Young, K. W., Selmi, T., Yacobi, R., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35660 · Cited by 570
Kuntz, E. M., Baquero, P., Michie, A. M., Dunn, K., Tardito, S., Holyoake, T. L., Helgason, G. V., & Gottlieb, E. (2017) · Nature Medicine · doi:10.1038/nm.4399 · Cited by 546
Akt‐mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
Bai, D., Ueno, L., & Vogt, P. K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24748 · Cited by 529
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Meads, M. B., Hazlehurst, L. A., & Dalton, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2223 · Cited by 520
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
Cortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Shen, Z.-X., Pasquini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 463
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Schoepfer, J., Jahnke, W., Berellini, G., Buonamici, S., Cotesta, S., Cowan-Jacob, S. W., Dodd, S., Drueckes, P., Fabbro, D., Gabriel, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01040 · Cited by 454
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25011 · Cited by 413
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25792 · Cited by 410
Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia
Hattori, A., Tsunoda, M., Konuma, T., Kobayashi, M., Nagy, T., Glushka, J., Tayyari, F., McSkimming, D., Kannan, N., Tojo, A., et al. (2017) · Nature · doi:10.1038/nature22314 · Cited by 401
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella-Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1199 · Cited by 375
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Rossari, F., Minutolo, F., & Orciuolo, E. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0624-2 · Cited by 371
Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M., Cortes, J. E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.006 · Cited by 363
Drug Transporters in Drug Efficacy and Toxicity
DeGorter, M. K., Xia, C. Q., Yang, J. J., & Kim, R. B. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134529 · Cited by 359
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hochhaus, A., Saussele, S., Rosti, G., Mahon, F.-X., Janssen, J. J. W. M., Hjorth-Hansen, H., Richter, J., & Buske, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx219 · Cited by 343
White, D. L., Saunders, V. A., Dang, P., Engler, J., Venables, A., Zrim, S., Zannettino, A., Lynch, K., Manley, P. W., & Hughes, T. (2007) · Blood · doi:10.1182/blood-2007-06-093617 · Cited by 331
A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia
Lee, S.-I., Celik, S., Logsdon, B. A., Lundberg, S. M., Martins, T. J., Oehler, V. G., Estey, E. H., Miller, C. P., Chien, S., Dai, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02465-5 · Cited by 327
Moving treatment-free remission into mainstream clinical practice in CML
Hughes, T. P., & Ross, D. M. (2016) · Blood · doi:10.1182/blood-2016-01-694265 · Cited by 317
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Bone Marrow Microenvironment in Multiple Myeloma Progression
Manier, S., Sacco, A., Leleu, X., Ghobrial, I. M., & Roccaro, A. M. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/157496 · Cited by 301
Huang, X., Cortes, J., & Kantarjian, H. (2012) · Cancer · doi:10.1002/cncr.26679 · Cited by 300
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Koptyra, M., Falinski, R., Nowicki, M. O., Stoklosa, T., Majsterek, I., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2006) · Blood · doi:10.1182/blood-2005-07-2815 · Cited by 298
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Chen, Y., Hu, Y., Zhang, H., Peng, C., & Li, S. (2009) · Nature Genetics · doi:10.1038/ng.389 · Cited by 293
Fabarius, A., Leitner, A., Hochhaus, A., Müller, M. C., Hanfstein, B., Haferlach, C., Göhring, G., Schlegelberger, B., Jotterand, M., Reiter, A., et al. (2011) · Blood · doi:10.1182/blood-2011-08-373902 · Cited by 288
Sallmyr, A., Fan, J., & Rassool, F. V. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.036 · Cited by 285
Yee, K. W. L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0764 · Cited by 285
ABCG2 – a transporter for all seasons
Sarkadi, B., Özvegy-Laczka, C., Német, K., & Váradi, A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.03.123 · Cited by 282
Nowicki, M. O., Falinski, R., Koptyra, M., Slupianek, A., Stoklosa, T., Gloc, E., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2004) · Blood · doi:10.1182/blood-2004-05-1941 · Cited by 278
Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Agarwal, S., M.S. Hartz, A., F. Elmquist, W., & Bauer, B. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797440186 · Cited by 272
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Prost, S., Relouzat, F., Spentchian, M., Ouzegdouh, Y., Saliba, J., Massonnet, G., Beressi, J.-P., Verhoeyen, E., Raggueneau, V., Maneglier, B., et al. (2015) · Nature · doi:10.1038/nature15248 · Cited by 272
Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
Mumprecht, S., Schürch, C., Schwaller, J., Solenthaler, M., & Ochsenbein, A. F. (2009) · Blood · doi:10.1182/blood-2008-09-179697 · Cited by 267
Imatinib: a selective tyrosine kinase inhibitor
Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T., & Zimmermann, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80599-8 · Cited by 265
Zhang, B., Li, M., McDonald, T., Holyoake, T. L., Moon, R. T., Campana, D., Shultz, L., & Bhatia, R. (2013) · Blood · doi:10.1182/blood-2012-02-412890 · Cited by 264
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0047 · Cited by 262
Nigam, S. K. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052713 · Cited by 262
The FoxO–Autophagy Axis in Health and Disease
Cheng, Z. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.07.009 · Cited by 255
Eide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.004 · Cited by 247
Beretta, G. L., Cassinelli, G., Pennati, M., Zuco, V., & Gatti, L. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.062 · Cited by 235
The Philadelphia chromosome in leukemogenesis
Kang, Z.-J., Liu, Y.-F., Xu, L.-Z., Long, Z.-J., Huang, D., Yang, Y., Liu, B., Feng, J.-X., Pan, Y.-J., Yan, J.-S., et al. (2016) · Chinese Journal of Cancer · doi:10.1186/s40880-016-0108-0 · Cited by 233
Interaction of Imatinib with Human Organic Ion Carriers
Hu, S., Franke, R. M., Filipski, K. K., Hu, C., Orwick, S. J., de Bruijn, E. A., Burger, H., Baker, S. D., & Sparreboom, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4913 · Cited by 232
Hegedűs, C., Özvegy‐Laczka, C., Apáti, Á., Magócsi, M., Német, K., Őrfi, L., Kéri, G., Katona, M., Takáts, Z., Váradi, A., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00383.x · Cited by 228
Kantarjian, H. M., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Issa, J., Garcia‐Manero, G., Rios, M. B., Shan, J., Andreeff, M., et al. (2003) · Cancer · doi:10.1002/cncr.11543 · Cited by 227
Heidel, F. H., Bullinger, L., Feng, Z., Wang, Z., Neff, T. A., Stein, L., Kalaitzidis, D., Lane, S. W., & Armstrong, S. A. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.02.017 · Cited by 225
Nimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V., & Bhalla, K. (2003) · Blood · doi:10.1182/blood-2002-08-2675 · Cited by 222
Soverini, S., Mancini, M., Bavaro, L., Cavo, M., & Martinelli, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0780-6 · Cited by 222
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
Burchert, A., Wang, Y., Cai, D., von Bubnoff, N., Paschka, P., Müller-Brüsselbach, S., Ottmann, O. G., Duyster, J., Hochhaus, A., & Neubauer, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403898 · Cited by 213
Branford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., Shahrin, N. H., Marum, J. E., Nataren, N., Parker, W. T., et al. (2018) · Blood · doi:10.1182/blood-2018-02-832253 · Cited by 210
Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
Hiwase, D. K., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., Eadie, L., To, L. B., Melo, J., Kumar, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5095 · Cited by 208
Patel, A. B., O’Hare, T., & Deininger, M. W. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.007 · Cited by 204
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s189391 · Cited by 200
Warsch, W., Kollmann, K., Eckelhart, E., Fajmann, S., Cerny-Reiterer, S., Hölbl, A., Gleixner, K. V., Dworzak, M., Mayerhofer, M., Hoermann, G., et al. (2011) · Blood · doi:10.1182/blood-2009-10-248211 · Cited by 194
Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation
Taya, Y., Ota, Y., Wilkinson, A. C., Kanazawa, A., Watarai, H., Kasai, M., Nakauchi, H., & Yamazaki, S. (2016) · Science · doi:10.1126/science.aag3145 · Cited by 192
HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells
Zhang, H., Li, H., Xi, H. S., & Li, S. (2012) · Blood · doi:10.1182/blood-2011-10-387381 · Cited by 191
Eliasson, L., Clifford, S., Barber, N., & Marin, D. (2011) · Leukemia Research · doi:10.1016/j.leukres.2010.10.017 · Cited by 190
Kim, D. H. (., Sriharsha, L., Xu, W., Kamel-Reid, S., Liu, X., Siminovitch, K., Messner, H. A., & Lipton, J. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0145 · Cited by 186
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
Soverini, S., Branford, S., Nicolini, F. E., Talpaz, M., Deininger, M. W. N., Martinelli, G., Müller, M. C., Radich, J. P., & Shah, N. P. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.09.011 · Cited by 185
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
Jabbour, E., & Kantarjian, H. (2016) · American Journal of Hematology · doi:10.1002/ajh.24275 · Cited by 183
Grossmann, V, Kohlmann, A., Zenger, M., Schindela, S., Eder, C., Weissmann, S., Schnittger, S., Kern, W., Müller, M. C., Hochhaus, A., et al. (2011) · Leukemia · doi:10.1038/leu.2010.298 · Cited by 180
The BCR gene and philadelphia chromosome-positive leukemogenesis.
Laurent, E., Talpaz, M., Kantarjian, H. M., & Kurzrock, R. (2001) · PubMed · Cited by 180
Agarwal, P., Isringhausen, S., Li, H., Paterson, A. J., He, J., Gomariz, Á., Nagasawa, T., Nombela-Arrieta, C., & Bhatia, R. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.02.018 · Cited by 176
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Caldemeyer, L., Dugan, M., Edwards, J., & Akard, L. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0309-2 · Cited by 173
Zhao, S., Konopleva, M. Y., Cabreira-Hansen, M. D. G., Xie, Z., Hu, W. S., Milella, M., Estrov, Z. E., Mills, G. B., & Andreeff, M. (2003) · Leukemia · doi:10.1038/sj.leu.2403220 · Cited by 167
Hazlehurst, L. A., & Dalton, W. S. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013156407224 · Cited by 162
Schmidt, M., Rinke, J., Schäfer, V., Schnittger, S., Kohlmann, A., Obstfelder, E., Kunert, C., Ziermann, J., Winkelmann, N., Eigendorff, E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.272 · Cited by 156
Yee, S. W., Brackman, D. J., Ennis, E. A., Sugiyama, Y., Kamdem, L. K., Blanchard, R. L., Galetin, A., Zhang, L., & Giacomini, K. M. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1098 · Cited by 155
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
Ritchie, E. K., Feldman, E. J., Christos, P. J., Rohan, S. D., Lagassa, C. B., Ippoliti, C., Scandura, J. M., Carlson, K., & Roboz, G. J. (2013) · Leukemia & Lymphoma · doi:10.3109/10428194.2012.762093 · Cited by 152
Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., & Hazlehurst, L. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0314 · Cited by 150
Cramer-Morales, K., Nieborowska-Skorska, M., Scheibner, K., Padget, M., Irvine, D. A., Sliwinski, T., Haas, K., Lee, J., Geng, H., Roy, D., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501072 · Cited by 145
Machine learning applications in the diagnosis of leukemia: Current trends and future directions
Salah, H. T., Muhsen, I. N., Salama, M. E., Owaidah, T. M., & Hashmi, S. K. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13089 · Cited by 145
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Hughes, A., & Yong, A. S. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00469 · Cited by 144
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 143
Expression patterns of microRNAs associated with CML phases and their disease related targets
Machová Poláková, K., Lopotová, T., Klamová, H., Burda, P., Trněný, M., Stopka, T., & Moravcová, J. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-41 · Cited by 141
Gaymes, T. J., Mufti, G. J., & Rassool, F. V. (2002) · PubMed · Cited by 137
Oki, Y., Kantarjian, H. M., Gharibyan, V., Jones, D., O'Brien, S., Verstovsek, S., Cortes, J., Morris, G. M., Garcia‐Manero, G., & Issa, J. J. (2007) · Cancer · doi:10.1002/cncr.22470 · Cited by 136
Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
Cortes, J., Rea, D., & Lipton, J. H. (2019) · American Journal of Hematology · doi:10.1002/ajh.25342 · Cited by 136
Cortes, J., Lipton, J. H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., Benichou, A.-C., Craig, A. R., Michallet, M., Nicolini, F. E., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415307 · Cited by 134
The physiological role of drug transporters
Liang, Y., Li, S., & Chen, L. (2015) · Protein & Cell · doi:10.1007/s13238-015-0148-2 · Cited by 133
Ma, L., Shan, Y., Bai, R., Xue, L., Eide, C. A., Ou, J., Zhu, L. J., Hutchinson, L., Cerny, J., Khoury, H. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009073 · Cited by 133
Million, R. P., & Van Etten, R. A. (2000) · Blood · doi:10.1182/blood.v96.2.664 · Cited by 133
Kim, T., Tyndel, M. S., Kim, H. J., Ahn, J.-S., Choi, S. H., Park, H. J., Kim, Y.-K., Kim, S. Y., Lipton, J. H., Zhang, Z., et al. (2017) · Blood · doi:10.1182/blood-2016-04-708560 · Cited by 133
Chaudhri, N. A. (2004) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2004.221 · Cited by 133
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
Quentmeier, H., Eberth, S., Romani, J., Zaborski, M., & Drexler, H. G. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-6 · Cited by 132
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-020-01464-z · Cited by 131
Christiansson, L., Söderlund, S., Svensson, E., Mustjoki, S., Bengtsson, M., Simonsson, B., Olsson-Strömberg, U., & Loskog, A. S. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055818 · Cited by 130
Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
Baquero, P., Dawson, A., Mukhopadhyay, A., Kuntz, E. M., Mitchell, R., Olivares, O., Ianniciello, A., Scott, M. T., Dunn, K., Nicastri, M. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0252-4 · Cited by 129
Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008) · Blood · doi:10.1182/blood-2007-10-116236 · Cited by 128
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Hsieh, Y.-C., Kirschner, K., & Copland, M. (2021) · Leukemia · doi:10.1038/s41375-021-01238-w · Cited by 123
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
Warsch, W., Walz, C., & Sexl, V. (2013) · Blood · doi:10.1182/blood-2013-02-485573 · Cited by 122
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia
Gandhi, V., Plunkett, W., & Cortes, J. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1283 · Cited by 118
Bavaro, L., Martelli, M., Cavo, M., & Soverini, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246141 · Cited by 115
Third-line therapy for chronic myeloid leukemia: current status and future directions
Cortes, J., & Lang, F. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01055-9 · Cited by 115
Rampalli, S., Pavithra, L., Bhatt, A., Kundu, T. K., & Chattopadhyay, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.19.8415-8429.2005 · Cited by 114
Down-regulation of BRCA1 in BCR-ABL–expressing hematopoietic cells
Deutsch, É., Jarrousse, S., Selimoglu‐Buet, D., Dugray, A., Bonnet, M., Vozenin, M., Guilhot, F., Turhan, A. G., Feunteun, J., & Bourhis, J. (2003) · Blood · doi:10.1182/blood-2002-10-3011 · Cited by 112
Redaelli, S., Mologni, L., Rostagno, R., Piazza, R., Magistroni, V., Ceccon, M., Viltadi, M., Flynn, D. L., & Gambacorti-Passerini, C. B. (2012) · American Journal of Hematology · doi:10.1002/ajh.23338 · Cited by 112
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML
Brück, O. E., Blom, S., Dufva, O., Turkki, R., Chheda, H., Ribeiro, A., Kovanen, P. E., Aittokallio, T. A., Koskenvesa, P., Kallioniemi, O., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0175-0 · Cited by 112
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
Villuendas, R., Steegmann, J. L., Pollán, M., Tracey, L., Granda, A., Fernández‐Ruiz, E., Casado, L., Martínez‐López, J., Martinez, P. B., Lombardía, L., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404197 · Cited by 111
Venetoclax: A new wave in hematooncology
Mihályová, J., Jelínek, T., Growková, K., Hrdinka, M., Šimíček, M., & Hájek, R. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.02.002 · Cited by 111
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
Frank, O., Brors, B., Fabarius, A. C., Li, L., Haak, M., Merk, S., Schwindel, U., Zheng, C., Müller, M. C., Gretz, N., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404270 · Cited by 110
Carter, B. Z., Mak, D. H. F., Schober, W. D., Cabreira-Hansen, M. D. G., Beran, M., McQueen, T. J., Chen, W., & Andreeff, M. (2005) · Blood · doi:10.1182/blood-2004-12-4704 · Cited by 110
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
Rousselot, P. H., Prost, S., Guilhot, J., Roy, L., Étienne, G., Legros, L., Charbonnier, A., Coiteux, V., Cony‐Makhoul, P., Huguet, F., et al. (2016) · Cancer · doi:10.1002/cncr.30490 · Cited by 106
Li, S. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701713689 · Cited by 105
Hochhaus, A., Breccia, M., Saglio, G., García-Gutiérrez, V., Réa, D., Janssen, J., & Apperley, J. (2020) · Leukemia · doi:10.1038/s41375-020-0842-9 · Cited by 105
Epigenetic inactivation of the hsa-miR-203 in haematological malignancies
Chim, C. S., Wong, K. Y., Leung, C. Y., Chung, L.-P., Hui, P. K., Chan, S. Y., & Yu, L. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01274.x · Cited by 104
MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia
Chakraborty, C., Sharma, A. R., Patra, B. C., Bhattacharya, M., Sharma, G., & Lee, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7977 · Cited by 104
A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers
Dunwell, T. L., Hesson, L. B., Rauch, T. A., Wang, L., Clark, R. E., Dallol, A., Gentle, D., Catchpoole, D. R., Maher, E. R., Pfeifer, G. P., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-44 · Cited by 103
Tobin, L. A., Robert, C., Rapoport, A. P., Gojo, I., Baer, M. R., Tomkinson, A. E., & Rassool, F. V. (2013) · Oncogene · doi:10.1038/onc.2012.203 · Cited by 102
Fiskus, W. C., Pranpat, M., Balasis, M. E., Bali, P., Estrella, V. C., Kumaraswamy, S., Rao, R., Rocha, K., Herger, B. E., Lee, F. Y., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0980 · Cited by 102
Dasatinib in chronic myeloid leukemia: a review
Tsimberidou, A.-M. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3425 · Cited by 101
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
Neul, C., Schaeffeler, E., Sparreboom, A., Laufer, S., Schwab, M. G., & Nies, A. T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.08.003 · Cited by 101
Metabolic dependencies and vulnerabilities in leukemia
Rashkovan, M., & Ferrando, A. A. (2019) · Genes & Development · doi:10.1101/gad.326470.119 · Cited by 100
Soverini, S., Bavaro, L., De Benedittis, C., Martelli, M., Iurlo, A., Orofino, N., Sica, S., Sorà, F., Lunghi, F., Ciceri, F., et al. (2020) · Blood · doi:10.1182/blood.2019002969 · Cited by 100
Heyes, N., Kapoor, P., & Kerr, I. D. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083030 · Cited by 99
Hochhaus, A., Saglio, G. N., Larson, R. A., Kim, D., Étienne, G., Rosti, G., Souza, C. A. D., Kurokawa, M., Kalaycio, M. E., Hoenekopp, A., et al. (2013) · Blood · doi:10.1182/blood-2012-04-423418 · Cited by 98
Cramer, K., Nieborowska-Skorska, M., Koptyra, M., Słupianek, A., Penserga, E. T. P., Eaves, C. J., Aulitzky, W. E., & Skórski, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1101 · Cited by 96
Brady, N., Gaymes, T. J., Cheung, M., Mufti, G. J., & Rassool, F. V. (2003) · PubMed · Cited by 93
Zhang, H.-M., Li, Q., Zhu, X., Liu, W., Hu, H., Liu, T., Cheng, F., You, Y., Zhong, Z., Zou, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2120 · Cited by 91
Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
Eadie, L. N., Hughes, T. P., & White, D. L. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.208 · Cited by 91
Zhou, H., Mak, P. Y., Mu, H., Mak, D. H., Zeng, Z., Cortes, J., Liu, Q., Andreeff, M., & Carter, B. Z. (2017) · Leukemia · doi:10.1038/leu.2017.87 · Cited by 91
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells
Abraham, A., Qiu, S., Chacko, B. K., Li, H., Paterson, A., He, J., Agarwal, P., Shah, M., Welner, R., Darley-Usmar, V. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127080 · Cited by 90
Nguyen, T. T., Mohrbacher, A., Tsai, Y., Groffen, J., Heisterkamp, N., Nichols, P. W., Yu, M. C., Lübbert, M., & Jones, P. A. (2000) · Blood · doi:10.1182/blood.v95.9.2990.009k08_2990_2992 · Cited by 87
The bone marrow microenvironment in health and disease at a glance
Kumar, R., Godavarthy, P. S., & Krause, D. S. (2018) · Journal of Cell Science · doi:10.1242/jcs.201707 · Cited by 87
Expression of the normal p53 gene induces differentiation of K562 cells.
Feinstein, E., Gale, R. P., Reed, J., & Canaani, E. (1992) · PubMed · Cited by 83
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
Sherbenou, D. W., Hantschel, O., Kaupe, I., Willis, S., Bumm, T., Turaga, L. P., Lange, T., Dao, K.-H., Press, R. D., Druker, B. J., et al. (2010) · Blood · doi:10.1182/blood-2008-10-183665 · Cited by 83
Maiti, A., Franquiz, M. J., Ravandi, F., Cortes, J. E., Jabbour, E. J., Sasaki, K., Marx, K. R., Daver, N. G., Kadia, T. M., Konopleva, M. Y., et al. (2020) · Acta Haematologica · doi:10.1159/000506346 · Cited by 82
Irvine, D. A., Zhang, B., Kinstrie, R., Tarafdar, A., Morrison, H., Campbell, V. L., Moka, H. A., Ho, Y., Nixon, C., Manley, P. W., et al. (2016) · Scientific Reports · doi:10.1038/srep25476 · Cited by 81
Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia
Balabanov, S., Braig, M., & Brümmendorf, T. H. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.03.003 · Cited by 78
p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation
Canitrot, Y., Falinski, R., Louat, T., Laurent, G., Cazaux, C., Hoffmann, J.-S., Lautier, D., & Skorski, T. (2003) · Blood · doi:10.1182/blood-2002-10-3207 · Cited by 76
Tipping, A. J., Deininger, M. W., Goldman, J. M., & Melo, J. V. (2003) · Experimental Hematology · doi:10.1016/j.exphem.2003.08.006 · Cited by 75
Bilich, T., Nelde, A., Bichmann, L., Roerden, M., Salih, H. R., Kowalewski, D. J., Schuster, H., Tsou, C.-C., Marcu, A., Neidert, M. C., et al. (2019) · Blood · doi:10.1182/blood-2018-07-866830 · Cited by 75
Wagle, M., Eiring, A. M., Wongchenko, M., Lu, S., Guan, Y., Wang, Y., Lackner, M., Amler, L., Hampton, G., Deininger, M. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.51 · Cited by 74
Soverini, S., Abruzzese, E., Bocchia, M., Bonifacio, M., Galimberti, S., Gozzini, A., Iurlo, A., Luciano, L., Pregno, P., Rosti, G., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0815-5 · Cited by 74
Bibi, S., Arslanhan, M. D., Langenfeld, F., Jeanningros, S., Cerny‐Reiterer, S., Hadzijusufovic, E., Tchertanov, L., Moriggl, R., Valent, P., & Arock, M. (2014) · Haematologica · doi:10.3324/haematol.2013.098442 · Cited by 73
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
Arrigoni, E., Re, M. D., Galimberti, S., Restante, G., Rofi, E., Crucitta, S., Baratè, C., Petrini, M., Danesi, R., & Paolo, A. D. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0175 · Cited by 73
New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
Westerweel, P. E., Boekhorst, P. A. W. T., Levin, M., & Cornelissen, J. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00665 · Cited by 73
Naka, K., Jomen, Y., Ishihara, K., Kim, J., Ishimoto, T., Bae, E., Mohney, R. P., Stirdivant, S. M., Oshima, H., Oshima, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9039 · Cited by 72
Ko, T. K., Javed, A., Lee, K. L., Pathiraja, T. N., Liu, X., Malik, S., Soh, S. X., Heng, X. T., Takahashi, N., Tan, J. H. J., et al. (2020) · Blood · doi:10.1182/blood.2020004834 · Cited by 72
The dynamics of adult haematopoiesis in the bone and bone marrow environment
Ho, M., Medcalf, R. L., Livesey, S. A., & Traianedes, K. (2015) · British Journal of Haematology · doi:10.1111/bjh.13445 · Cited by 71
Structure and function of Gab2 and its role in cancer (Review)
DING, C.-B., YU, W.-N., FENG, J.-H., & LUO, J.-M. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3951 · Cited by 71
Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
Chen, Y., Peng, C., Abraham, S. A., Shan, Y., Guo, Z., DeSouza, N. H., Cheloni, G., Li, D., Holyoake, T. L., & Li, S. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66129 · Cited by 70
Eadie, L. N., Dang, P. G., Saunders, V. A., Yeung, D. T. O., Osborn, M. P., Grigg, A., Hughes, T. P., & White, D. L. (2016) · Leukemia · doi:10.1038/leu.2016.179 · Cited by 69
Wang, W., Cortes, J. E., Lin, P., Beaty, M. W., Ai, D., Amin, H. M., McDonnell, T. J., Ok, C. Y., Kantarjian, H. M., Medeiros, L. J., et al. (2015) · Blood · doi:10.1182/blood-2015-05-646489 · Cited by 68
Singh, P., Kumar, V., Gupta, S. K., Kumari, G., & Verma, M. (2021) · Medical Oncology · doi:10.1007/s12032-021-01462-5 · Cited by 67
Chandran, R. K., Geetha, N., Sakthivel, K. M., Kumar, R. S., Krishna, K. M. N. J., & Sreedharan, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00088 · Cited by 67
Mian, A. A., Rafiei, A., Haberbosch, I., Zeifman, A. A., Titov, I. Y., Stroylov, V. S., Metodieva, A., Stroganov, O. V., Novikov, F. N., Brill, B., et al. (2014) · Leukemia · doi:10.1038/leu.2014.326 · Cited by 66
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Massimino, M., Stella, S., Tirrò, E., Romano, C., Pennisi, M. S., Puma, A., Manzella, L., Zanghì, A., Stagno, F., Raimondo, F. D., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0805-1 · Cited by 66
Sundaram, D. N. M., Jiang, X., Brandwein, J. M., Valencia‐Serna, J., Remant, K. C. B., & Uludağ, H. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.007 · Cited by 66
Podszywalow‐Bartnicka, P., Wołczyk, M., Kusio-Kobiałka, M., Wolanin, K., Skowronek, K., Nieborowska-Skorska, M., Dasgupta, Y., Skórski, T., & Piwocka, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.965013 · Cited by 65
MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML
Suresh, S., McCallum, L., Lu, W., Lazar, N., Perbal, B., & Irvine, A. E. (2011) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-011-0139-x · Cited by 65
Zhang, X., Yang, Y., Yang, Y., Chen, H., Tu, H., & Li, J. (2020) · Stem Cells International · doi:10.1155/2020/8890201 · Cited by 65
Cortes, J., Digumarti, R., Parikh, P. M., Wetzler, M., Lipton, J. H., Hochhaus, A., Craig, A. R., Benichou, A. ‐., Nicolini, F. E., Kantarjian, H. M., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23408 · Cited by 64
Eadie, L. N., Saunders, V. A., Branford, S., White, D. L., & Hughes, T. P. (2018) · Oncotarget · doi:10.18632/oncotarget.24393 · Cited by 63
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
Maia, R. C., Vasconcelos, F. D. C., de Souza, P. S., & Rumjanek, V. M. (2018) · Molecules · doi:10.3390/molecules23010119 · Cited by 63
Ohanian, M., Tari Ashizawa, A., Garcia-Manero, G., Pemmaraju, N., Kadia, T., Jabbour, E., Ravandi, F., Borthakur, G., Andreeff, M., Konopleva, M., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30021-8 · Cited by 63
Au, A., Baba, A. A., Goh, A. S., Fadilah, S. A. W., Teh, A. K. H., Rosline, H., & Ankathil, R. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.01.009 · Cited by 62
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
Hoermann, G., Greiner, G., & Valent, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/869242 · Cited by 61
Epigenetic drugs against cancer: an evolving landscape
Costanzo, A. D., Gaudio, N. D., Migliaccio, A., & Altucci, L. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1315-6 · Cited by 61
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
Togasaki, E., Takeda, J., Yoshida, K., Shiozawa, Y., Takeuchi, M., Oshima, M., Saraya, A., Iwama, A., Yokote, K., Sakaida, E., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.36 · Cited by 61
OCT1 and imatinib transport in CML: is it clinically relevant?
Watkins, D. B., Hughes, T. P., & White, D. L. (2015) · Leukemia · doi:10.1038/leu.2015.170 · Cited by 60
Role of Epigenetics in Chronic Myeloid Leukemia
Poláková, K. M., Koblihova, J., & Stopka, T. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0152-z · Cited by 60
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors
Wöhrle, F. U., Halbach, S., Aumann, K., Schwemmers, S., Braun, S. L., Auberger, P., Schramek, D., Penninger, J. M., Laßmann, S., Werner, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.222 · Cited by 58
Sweet, K. L., Hazlehurst, L., Sahakian, E., Powers, J. J., Nodzon, L., Kayali, F., Hyland, K. A., Nelson, A. M., & Pinilla-Ibarz, J. A. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.10.002 · Cited by 58
Kizilors, A., Crisà, E., Lea, N., Passera, R., Mian, S., Anwar, J., Best, S., Nicolini, F. E., Ireland, R., Aldouri, M., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30027-4 · Cited by 58
Influence of Bone Marrow Microenvironment on Leukemic Stem Cells
Agarwal, P., & Bhatia, R. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.007 · Cited by 57
Role of STAT3 in Transformation and Drug Resistance in CML
Nair, R. R., Tolentino, J. H., & Hazlehurst, L. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00030 · Cited by 56
Mechanisms of resistance to BCR–ABL kinase inhibitors
Diamond, J., & Melo, J. V. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.546920 · Cited by 56
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
Cang, S., & Liu, D. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-15 · Cited by 56
Saiki, A. Y., Caenepeel, S., Yu, D., Lofgren, J. A., Osgood, T., Robertson, R., Canon, J., Su, C., Jones, A., Zhao, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1918 · Cited by 55
Cited by
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., Lipton, J. H., Malhotra, H., Niederwieser, D., Radich, J., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02664-w · Cited by 226
“[46].”
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Qin, Y., Han, S., Yu, Y., Ding, Q., Ran, M., Yang, M., Liu, Y., Li, Y., Lu, L., Liu, Y., et al. (2024) · Liver International · doi:10.1111/liv.15953 · Cited by 112
Rinaldi, I., & Winston, K. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s382090 · Cited by 128
Olverembatinib: First Approval
Dhillon, S. (2022) · Drugs · doi:10.1007/s40265-022-01680-9 · Cited by 71
Metadata
- Authors
- Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B.
- Affiliations
- Centro de Investigação em Meio Ambiente Genética e Oncobiologia (PT)
- Nottingham Trent University (GB)
- Hospital da Luz Lisboa, 1500-650 Lisbon, Portugal
- Cancer Research Center (CiC-IBMCC, CSIC/USAL/IBSAL, Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca (USAL) and Instituto de Investigación Biomédica de Salamanca (IBSAL)), 37007 Salamanca, Spain
- National and Kapodistrian University of Athens (GR)
- Laboratory of Oncobiology and Hematology, University Clinic of Hematology, Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-09-26
- Volume
- 13
- Issue
- 19
- Pages
- 4820
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8508378
- OpenAlex
- W3204122798
- Cited by
- 204
- References
- 318
- Citations by year
- 2026: 42 · 2025: 51 · 2024: 38 · 2023: 46 · 2022: 27
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (acceptedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Estudo Geral (Universidad de Coimbra) (submittedVersion, cc-by)
- Funders
- Fundação para a Ciência e a Tecnologia (UIDB/04539/2020, UIDP/04539/2020)
- Ministerio de Ciencia e Innovación (PI18/00591)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- chronic myeloid leukemia, tyrosine kinase inhibitors, imatinib, drug resistance, BCR-ABL fusion gene, medication adherence, next-generation sequencing, digital PCR, artificial intelligence, mathematical modeling, resistance mechanisms, treatment options
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.